The Idiopathic Pulmonary Fibrosis Treatment Drug Market continues to expand as pulmonologists and interstitial lung disease specialists confront the progressive and irreversible nature of this devastating fibrotic disorder. With idiopathic pulmonary fibrosis representing the most common and lethal form of idiopathic interstitial pneumonia, characterized by relentless decline in lung function...